Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer
Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer
复制标题
全身免疫炎症指数预测晚期胰腺癌患者的预后
DOI：
10.1186/s12967-019-1782-x
复制
发表时间：
2019-01-18
影响因子：
7.4
通讯作者：
Chen, Hao
中科院分区：
文献类型：
--
作者：
Zhang, Ke;Hua, Yong-Qiang;Chen, Hao
研究背景全身炎症和免疫功能紊乱与多种恶性肿瘤的进展和转移有关。本回顾性研究的目的是评估治疗前全身免疫炎症指数（SII）在晚期胰腺癌患者中的预后意义。MethodsIn total，419例诊断为晚期胰腺癌的患者，2011年1月至2015年12月，回顾性入组。SII是基于2011年至2013年的197例患者的训练集开发的，并在2014年至2015年的222例患者的独立队列中进行了验证。收集基线临床病理学特征数据;治疗前实验室变量，如中性粒细胞、淋巴细胞和血小板绝对计数;碳水化合物抗原19-9（CA 19 -9）、总胆红素（TBIL）、白蛋白（ALB）、碱性磷酸酶（ALP）、丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）水平。评估了临床病理特征与SII之间的相关性。使用Kaplan-Meier生存曲线计算总生存期，并使用对数秩检验进行比较。结果以SII为440为最佳分界点，将训练队列中的晚期胰腺癌患者分为高（> 440）和低（≤ 440）SII组。单变量和多变量分析显示，SII是总生存期的独立预测因素。SII的预后意义被证实在正常和升高的CA 19 -9 level.ConclusionThe基线SII作为一个独立的预后指标为晚期胰腺癌患者，并可用于与正常和升高的CA 19 -9水平的患者。
BackgroundSystemic inflammation and immune dysfunction have been proved to be associated with cancer progression and metastasis in various malignancies. The aim of this retrospective study was to evaluate the prognostic significance of pre-treatment systemic immune-inflammation index (SII) in patients with advanced pancreatic cancer.MethodsIn total, 419 patients diagnosed with advanced pancreatic cancer, between January 2011 and December 2015, were retrospectively enrolled. The SII was developed based on a training set of 197 patients from 2011 to 2013 and validated in an independent cohort of 222 patients from 2014 to 2015. Data on baseline clinicopathologic characteristics; pre-treatment laboratory variables such as absolute neutrophil, lymphocyte, and platelet counts; and carbohydrate antigen 19-9 (CA19-9), total bilirubin (TBIL), albumin (ALB), alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate transaminase (AST) levels were collected. The association between clinicopathologic characteristics and SII was assessed. The overall survival was calculated using the Kaplan–Meier survival curves and compared using the log-rank test. Univariate and multivariate Cox proportional hazard regression models were used to analyze the prognostic value of the SII.ResultAn optimal cutoff point for the SII of 440 stratified the patients with advanced pancreatic cancer into high (> 440) and low (≤ 440) SII groups in the training cohort. Univariate and multivariate analyses revealed that the SII was an independent predictor for overall survival. The prognostic significance of the SII was confirmed in both normal and elevated CA19-9 levels.ConclusionThe baseline SII serves as an independent prognostic marker for patients with advanced pancreatic cancer and can be used in patients with both normal and elevated CA19-9 levels.